Kernicterus Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034
The 7 major kernicterus markets reached a value of US$ 2.0 Billion in 2023. Looking forward, IMARC Group expects the 7MM to reach US$ 2.5 Billion by 2034, exhibiting a growth rate (CAGR) of 1.92% during 2024-2034.
The kernicterus market has been comprehensively analyzed in IMARC's new report titled "Kernicterus Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034". Kernicterus refers to a rare but serious neurological disorder that primarily affects newborns. It is caused by the accumulation of excessive bilirubin in the brain, a yellow pigment produced when red blood cells are broken down. Bilirubin buildup occurs due to the inability of the infant's immature liver to efficiently process and excrete it, leading to its toxic effects on the central nervous system. The symptoms of kernicterus can manifest as lethargy, poor feeding, high-pitched crying, arching of the back, and muscle stiffness. As the condition progresses, more severe indications like deafness, vision problems, intellectual disabilities, and even involuntary muscle movements can emerge. The diagnosis of the ailment includes a combination of clinical evaluation, assessing the infant's neurological symptoms, and measuring serum bilirubin levels. High concentrations of bilirubin in the blood, along with visible signs of neural dysfunction, often prompt further diagnostic tests, such as brain imaging, to determine the extent of brain damage.
The escalating incidence of elevated levels of unconjugated bilirubin in the blood, leading to its deposition in brain tissues and subsequent neurological impairments, is primarily driving the kernicterus market. In addition to this, the rising prevalence of various associated risk factors in newborns, such as premature birth, blood group incompatibility, inadequate feeding, infections, etc., is also creating a positive outlook for the market. Moreover, the widespread adoption of phototherapy, which utilizes light waves to convert bilirubin into water-soluble forms that can be more easily excreted by the liver, thereby alleviating disease symptoms, is further bolstering the market growth. Apart from this, the inflating usage of intravenous immunoglobulin (IVIG) therapy to counteract antibodies responsible for the accelerated breakdown of red blood cells is acting as another significant growth-inducing factor. Additionally, the escalating application of early screening and educational campaigns targeted at parents and healthcare professionals, which emphasize the significance of prompt detection and intervention of the illness, is also propelling the market growth. Furthermore, the emerging popularity of effective medical procedures, such as exchange transfusions, that help to replace the affected infant’s damaged blood with fresh blood, is expected to drive the kernicterus market during the forecast period.
IMARC Group's new report provides an exhaustive analysis of the kernicterus market in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report the United States has the largest patient pool for kernicterus and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario and unmet medical needs, etc. have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the kernicterus market in any manner.
Time Period of the Study
Base Year: 2023
Historical Period: 2018-2023
Market Forecast: 2024-2034
Countries Covered
United States
Germany
France
United Kingdom
Italy
Spain
Japan
Analysis Covered Across Each Country
Historical, current, and future epidemiology scenario
Historical, current, and future performance of the kernicterus market
Historical, current, and future performance of various therapeutic categories in the market
Sales of various drugs across the kernicterus market
Reimbursement scenario in the market
In-market and pipeline drugs
Competitive Landscape:
This report also provides a detailed analysis of the current kernicterus marketed drugs and late-stage pipeline drugs.
In-Market Drugs
Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance
Late-Stage Pipeline Drugs
Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance
Key Questions Answered in this Report:
Market Insights
How has the kernicterus market performed so far and how will it perform in the coming years?
What are the markets shares of various therapeutic segments in 2023 and how are they expected to perform till 2034?
What was the country-wise size of the kernicterus market across the seven major markets in 2023 and what will it look like in 2034?
What is the growth rate of the kernicterus market across the seven major markets and what will be the expected growth over the next ten years?
What are the key unmet needs in the market?
Epidemiology Insights
What is the number of prevalent cases (2018-2034) of kernicterus across the seven major markets?
What is the number of prevalent cases (2018-2034) of kernicterus by age across the seven major markets?
What is the number of prevalent cases (2018-2034) of kernicterus by gender across the seven major markets?
How many patients are diagnosed (2018-2034) with kernicterus across the seven major markets?
What is the size of the kernicterus patient pool (2018-2023) across the seven major markets?
What would be the forecasted patient pool (2024-2034) across the seven major markets?
What are the key factors driving the epidemiological trend of kernicterus?
What will be the growth rate of patients across the seven major markets?
Kernicterus: Current Treatment Scenario, Marketed Drugs and Emerging Therapies
What are the current marketed drugs and what are their market performance?
What are the key pipeline drugs and how are they expected to perform in the coming years?
How safe are the current marketed drugs and what are their efficacies?
How safe are the late-stage pipeline drugs and what are their efficacies?
What are the current treatment guidelines for kernicterus drugs across the seven major markets?
Who are the key companies in the market and what are their market shares?
What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the kernicterus market?
What are the key regulatory events related to the kernicterus market?
What is the structure of clinical trial landscape by status related to the kernicterus market?
What is the structure of clinical trial landscape by phase related to the kernicterus market?
What is the structure of clinical trial landscape by route of administration related to the kernicterus market?
The kernicterus market has been comprehensively analyzed in IMARC's new report titled "Kernicterus Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034". Kernicterus refers to a rare but serious neurological disorder that primarily affects newborns. It is caused by the accumulation of excessive bilirubin in the brain, a yellow pigment produced when red blood cells are broken down. Bilirubin buildup occurs due to the inability of the infant's immature liver to efficiently process and excrete it, leading to its toxic effects on the central nervous system. The symptoms of kernicterus can manifest as lethargy, poor feeding, high-pitched crying, arching of the back, and muscle stiffness. As the condition progresses, more severe indications like deafness, vision problems, intellectual disabilities, and even involuntary muscle movements can emerge. The diagnosis of the ailment includes a combination of clinical evaluation, assessing the infant's neurological symptoms, and measuring serum bilirubin levels. High concentrations of bilirubin in the blood, along with visible signs of neural dysfunction, often prompt further diagnostic tests, such as brain imaging, to determine the extent of brain damage.
The escalating incidence of elevated levels of unconjugated bilirubin in the blood, leading to its deposition in brain tissues and subsequent neurological impairments, is primarily driving the kernicterus market. In addition to this, the rising prevalence of various associated risk factors in newborns, such as premature birth, blood group incompatibility, inadequate feeding, infections, etc., is also creating a positive outlook for the market. Moreover, the widespread adoption of phototherapy, which utilizes light waves to convert bilirubin into water-soluble forms that can be more easily excreted by the liver, thereby alleviating disease symptoms, is further bolstering the market growth. Apart from this, the inflating usage of intravenous immunoglobulin (IVIG) therapy to counteract antibodies responsible for the accelerated breakdown of red blood cells is acting as another significant growth-inducing factor. Additionally, the escalating application of early screening and educational campaigns targeted at parents and healthcare professionals, which emphasize the significance of prompt detection and intervention of the illness, is also propelling the market growth. Furthermore, the emerging popularity of effective medical procedures, such as exchange transfusions, that help to replace the affected infant’s damaged blood with fresh blood, is expected to drive the kernicterus market during the forecast period.
IMARC Group's new report provides an exhaustive analysis of the kernicterus market in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report the United States has the largest patient pool for kernicterus and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario and unmet medical needs, etc. have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the kernicterus market in any manner.
Time Period of the Study
Base Year: 2023
Historical Period: 2018-2023
Market Forecast: 2024-2034
Countries Covered
United States
Germany
France
United Kingdom
Italy
Spain
Japan
Analysis Covered Across Each Country
Historical, current, and future epidemiology scenario
Historical, current, and future performance of the kernicterus market
Historical, current, and future performance of various therapeutic categories in the market
Sales of various drugs across the kernicterus market
Reimbursement scenario in the market
In-market and pipeline drugs
Competitive Landscape:
This report also provides a detailed analysis of the current kernicterus marketed drugs and late-stage pipeline drugs.
In-Market Drugs
Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance
Late-Stage Pipeline Drugs
Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance
Key Questions Answered in this Report:
Market Insights
How has the kernicterus market performed so far and how will it perform in the coming years?
What are the markets shares of various therapeutic segments in 2023 and how are they expected to perform till 2034?
What was the country-wise size of the kernicterus market across the seven major markets in 2023 and what will it look like in 2034?
What is the growth rate of the kernicterus market across the seven major markets and what will be the expected growth over the next ten years?
What are the key unmet needs in the market?
Epidemiology Insights
What is the number of prevalent cases (2018-2034) of kernicterus across the seven major markets?
What is the number of prevalent cases (2018-2034) of kernicterus by age across the seven major markets?
What is the number of prevalent cases (2018-2034) of kernicterus by gender across the seven major markets?
How many patients are diagnosed (2018-2034) with kernicterus across the seven major markets?
What is the size of the kernicterus patient pool (2018-2023) across the seven major markets?
What would be the forecasted patient pool (2024-2034) across the seven major markets?
What are the key factors driving the epidemiological trend of kernicterus?
What will be the growth rate of patients across the seven major markets?
Kernicterus: Current Treatment Scenario, Marketed Drugs and Emerging Therapies
What are the current marketed drugs and what are their market performance?
What are the key pipeline drugs and how are they expected to perform in the coming years?
How safe are the current marketed drugs and what are their efficacies?
How safe are the late-stage pipeline drugs and what are their efficacies?
What are the current treatment guidelines for kernicterus drugs across the seven major markets?
Who are the key companies in the market and what are their market shares?
What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the kernicterus market?
What are the key regulatory events related to the kernicterus market?
What is the structure of clinical trial landscape by status related to the kernicterus market?
What is the structure of clinical trial landscape by phase related to the kernicterus market?
What is the structure of clinical trial landscape by route of administration related to the kernicterus market?
1 PREFACE
2 SCOPE AND METHODOLOGY
2.1 Objectives of the Study
2.2 Stakeholders
2.3 Data Sources
2.3.1 Primary Sources
2.3.2 Secondary Sources
2.4 Market Estimation
2.4.1 Bottom-Up Approach
2.4.2 Top-Down Approach
2.5 Forecasting Methodology
3 EXECUTIVE SUMMARY
4 KERNICTERUS - INTRODUCTION
4.1 Overview
4.2 Regulatory Process
4.3 Epidemiology (2018-2023) and Forecast (2024-2034)
4.4 Market Overview (2018-2023) and Forecast (2024-2034)
4.5 Competitive Intelligence
5 KERNICTERUS - DISEASE OVERVIEW
5.1 Introduction
5.2 Symptoms and Diagnosis
5.3 Pathophysiology
5.4 Causes and Risk Factors
5.5 Treatment
6 PATIENT JOURNEY
7 KERNICTERUS - EPIDEMIOLOGY AND PATIENT POPULATION
7.1 Epidemiology - Key Insights
7.2 Epidemiology Scenario - Top 7 Markets
7.2.1 Epidemiology Scenario (2018-2023)
7.2.2 Epidemiology Forecast (2024-2034)
7.2.3 Epidemiology by Age (2018-2034)
7.2.4 Epidemiology by Gender (2018-2034)
7.2.5 Diagnosed Cases (2018-2034)
7.2.6 Patient Pool/Treated Cases (2018-2034)
7.3 Epidemiology Scenario - United States
7.3.1 Epidemiology Scenario (2018-2023)
7.3.2 Epidemiology Forecast (2024-2034)
7.3.3 Epidemiology by Age (2018-2034)
7.3.4 Epidemiology by Gender (2018-2034)
7.3.5 Diagnosed Cases (2018-2034)
7.3.6 Patient Pool/Treated Cases (2018-2034)
7.4 Epidemiology Scenario - Germany
7.4.1 Epidemiology Scenario (2018-2023)
7.4.2 Epidemiology Forecast (2024-2034)
7.4.3 Epidemiology by Age (2018-2034)
7.4.4 Epidemiology by Gender (2018-2034)
7.4.5 Diagnosed Cases (2018-2034)
7.4.6 Patient Pool/Treated Cases (2018-2034)
7.5 Epidemiology Scenario - France
7.5.1 Epidemiology Scenario (2018-2023)
7.5.2 Epidemiology Forecast (2024-2034)
7.5.3 Epidemiology by Age (2018-2034)
7.5.4 Epidemiology by Gender (2018-2034)
7.5.5 Diagnosed Cases (2018-2034)
7.5.6 Patient Pool/Treated Cases (2018-2034)
7.6 Epidemiology Scenario - United Kingdom
7.6.1 Epidemiology Scenario (2018-2023)
7.6.2 Epidemiology Forecast (2024-2034)
7.6.3 Epidemiology by Age (2018-2034)
7.6.4 Epidemiology by Gender (2018-2034)
7.6.5 Diagnosed Cases (2018-2034)
7.6.6 Patient Pool/Treated Cases (2018-2034)
7.7 Epidemiology Scenario - Italy
7.7.1 Epidemiology Scenario (2018-2023)
7.7.2 Epidemiology Forecast (2024-2034)
7.7.3 Epidemiology by Age (2018-2034)
7.7.4 Epidemiology by Gender (2018-2034)
7.7.5 Diagnosed Cases (2018-2034)
7.7.6 Patient Pool/Treated Cases (2018-2034)
7.8 Epidemiology Scenario - Spain
7.8.1 Epidemiology Scenario (2018-2023)
7.8.2 Epidemiology Forecast (2024-2034)
7.8.3 Epidemiology by Age (2018-2034)
7.8.4 Epidemiology by Gender (2018-2034)
7.8.5 Diagnosed Cases (2018-2034)
7.8.6 Patient Pool/Treated Cases (2018-2034)
7.9 Epidemiology Scenario - Japan
7.9.1 Epidemiology Scenario (2018-2023)
7.9.2 Epidemiology Forecast (2024-2034)
7.9.3 Epidemiology by Age (2018-2034)
7.9.4 Epidemiology by Gender (2018-2034)
7.9.5 Diagnosed Cases (2018-2034)
7.9.6 Patient Pool/Treated Cases (2018-2034)
8 KERNICTERUS - TREATMENT ALGORITHM, GUIDELINES, AND MEDICAL PRACTICES
8.1 Guidelines, Management and Treatment
8.2 Treatment Algorithm
9 KERNICTERUS - UNMET NEEDS
10 KERNICTERUS - KEY ENDPOINTS OF TREATMENT
11 KERNICTERUS - MARKETED PRODUCTS
11.1 List of Kernicterus Marketed Drugs Across the Top 7 Markets
11.1.1 Drug Name – Company Name
11.1.1.1 Drug Overview
11.1.1.2 Mechanism of Action
11.1.1.3 Regulatory Status
11.1.1.4 Clinical Trial Results
11.1.1.5 Sales Across Major Markets
Kindly note that the complete list of marketed drugs has been provided in the report.
12 KERNICTERUS - PIPELINE DRUGS
12.1 List of Kernicterus Pipeline Drugs Across the Top 7 Markets
12.1.1 Drug Name – Company Name
12.1.1.1 Drug Overview
12.1.1.2 Mechanism of Action
12.1.1.3 Clinical Trial Results
12.1.1.4 Safety and Efficacy
12.1.1.5 Regulatory Status
Kindly note that the complete list of pipeline drugs has been provided in the report.
13. KERNICTERUS - ATTRIBUTE ANALYSIS OF KEY MARKETED AND PIPELINE DRUGS
14. KERNICTERUS – CLINICAL TRIAL LANDSCAPE
14.1 Drugs by Status
14.2 Drugs by Phase
14.3 Drugs by Route of Administration
14.4 Key Regulatory Events
15 KERNICTERUS - MARKET SCENARIO
15.1 Market Scenario - Key Insights
15.2 Market Scenario - Top 7 Markets
15.2.1 Kernicterus - Market Size
15.2.1.1 Market Size (2018-2023)
15.2.1.2 Market Forecast (2024-2034)
15.2.2 Kernicterus - Market Size by Therapies
15.2.2.1 Market Size by Therapies (2018-2023)
15.2.2.2 Market Forecast by Therapies (2024-2034)
15.3 Market Scenario - United States
15.3.1 Kernicterus - Market Size
15.3.1.1 Market Size (2018-2023)
15.3.1.2 Market Forecast (2024-2034)
15.3.2 Kernicterus - Market Size by Therapies
15.3.2.1 Market Size by Therapies (2018-2023)
15.3.2.2 Market Forecast by Therapies (2024-2034)
15.3.3 Kernicterus - Access and Reimbursement Overview
15.4 Market Scenario - Germany
15.4.1 Kernicterus - Market Size
15.4.1.1 Market Size (2018-2023)
15.4.1.2 Market Forecast (2024-2034)
15.4.2 Kernicterus - Market Size by Therapies
15.4.2.1 Market Size by Therapies (2018-2023)
15.4.2.2 Market Forecast by Therapies (2024-2034)
15.4.3 Kernicterus - Access and Reimbursement Overview
15.5 Market Scenario - France
15.5.1 Kernicterus - Market Size
15.5.1.1 Market Size (2018-2023)
15.5.1.2 Market Forecast (2024-2034)
15.5.2 Kernicterus - Market Size by Therapies
15.5.2.1 Market Size by Therapies (2018-2023)
15.5.2.2 Market Forecast by Therapies (2024-2034)
15.5.3 Kernicterus - Access and Reimbursement Overview
15.6 Market Scenario - United Kingdom
15.6.1 Kernicterus - Market Size
15.6.1.1 Market Size (2018-2023)
15.6.1.2 Market Forecast (2024-2034)
15.6.2 Kernicterus - Market Size by Therapies
15.6.2.1 Market Size by Therapies (2018-2023)
15.6.2.2 Market Forecast by Therapies (2024-2034)
15.6.3 Kernicterus - Access and Reimbursement Overview
15.7 Market Scenario - Italy
15.7.1 Kernicterus - Market Size
15.7.1.1 Market Size (2018-2023)
15.7.1.2 Market Forecast (2024-2034)
15.7.2 Kernicterus - Market Size by Therapies
15.7.2.1 Market Size by Therapies (2018-2023)
15.7.2.2 Market Forecast by Therapies (2024-2034)
15.7.3 Kernicterus - Access and Reimbursement Overview
15.8 Market Scenario - Spain
15.8.1 Kernicterus - Market Size
15.8.1.1 Market Size (2018-2023)
15.8.1.2 Market Forecast (2024-2034)
15.8.2 Kernicterus - Market Size by Therapies
15.8.2.1 Market Size by Therapies (2018-2023)
15.8.2.2 Market Forecast by Therapies (2024-2034)
15.8.3 Kernicterus - Access and Reimbursement Overview
15.9 Market Scenario - Japan
15.9.1 Kernicterus - Market Size
15.9.1.1 Market Size (2018-2023)
15.9.1.2 Market Forecast (2024-2034)
15.9.2 Kernicterus - Market Size by Therapies
15.9.2.1 Market Size by Therapies (2018-2023)
15.9.2.2 Market Forecast by Therapies (2024-2034)
15.9.3 Kernicterus - Access and Reimbursement Overview
16 KERNICTERUS - RECENT EVENTS AND INPUTS FROM KEY OPINION LEADERS
17 KERNICTERUS MARKET - SWOT ANALYSIS
17.1 Strengths
17.2 Weaknesses
17.3 Opportunities
17.4 Threats
18 KERNICTERUS MARKET – STRATEGIC RECOMMENDATIONS
19 APPENDIX
2 SCOPE AND METHODOLOGY
2.1 Objectives of the Study
2.2 Stakeholders
2.3 Data Sources
2.3.1 Primary Sources
2.3.2 Secondary Sources
2.4 Market Estimation
2.4.1 Bottom-Up Approach
2.4.2 Top-Down Approach
2.5 Forecasting Methodology
3 EXECUTIVE SUMMARY
4 KERNICTERUS - INTRODUCTION
4.1 Overview
4.2 Regulatory Process
4.3 Epidemiology (2018-2023) and Forecast (2024-2034)
4.4 Market Overview (2018-2023) and Forecast (2024-2034)
4.5 Competitive Intelligence
5 KERNICTERUS - DISEASE OVERVIEW
5.1 Introduction
5.2 Symptoms and Diagnosis
5.3 Pathophysiology
5.4 Causes and Risk Factors
5.5 Treatment
6 PATIENT JOURNEY
7 KERNICTERUS - EPIDEMIOLOGY AND PATIENT POPULATION
7.1 Epidemiology - Key Insights
7.2 Epidemiology Scenario - Top 7 Markets
7.2.1 Epidemiology Scenario (2018-2023)
7.2.2 Epidemiology Forecast (2024-2034)
7.2.3 Epidemiology by Age (2018-2034)
7.2.4 Epidemiology by Gender (2018-2034)
7.2.5 Diagnosed Cases (2018-2034)
7.2.6 Patient Pool/Treated Cases (2018-2034)
7.3 Epidemiology Scenario - United States
7.3.1 Epidemiology Scenario (2018-2023)
7.3.2 Epidemiology Forecast (2024-2034)
7.3.3 Epidemiology by Age (2018-2034)
7.3.4 Epidemiology by Gender (2018-2034)
7.3.5 Diagnosed Cases (2018-2034)
7.3.6 Patient Pool/Treated Cases (2018-2034)
7.4 Epidemiology Scenario - Germany
7.4.1 Epidemiology Scenario (2018-2023)
7.4.2 Epidemiology Forecast (2024-2034)
7.4.3 Epidemiology by Age (2018-2034)
7.4.4 Epidemiology by Gender (2018-2034)
7.4.5 Diagnosed Cases (2018-2034)
7.4.6 Patient Pool/Treated Cases (2018-2034)
7.5 Epidemiology Scenario - France
7.5.1 Epidemiology Scenario (2018-2023)
7.5.2 Epidemiology Forecast (2024-2034)
7.5.3 Epidemiology by Age (2018-2034)
7.5.4 Epidemiology by Gender (2018-2034)
7.5.5 Diagnosed Cases (2018-2034)
7.5.6 Patient Pool/Treated Cases (2018-2034)
7.6 Epidemiology Scenario - United Kingdom
7.6.1 Epidemiology Scenario (2018-2023)
7.6.2 Epidemiology Forecast (2024-2034)
7.6.3 Epidemiology by Age (2018-2034)
7.6.4 Epidemiology by Gender (2018-2034)
7.6.5 Diagnosed Cases (2018-2034)
7.6.6 Patient Pool/Treated Cases (2018-2034)
7.7 Epidemiology Scenario - Italy
7.7.1 Epidemiology Scenario (2018-2023)
7.7.2 Epidemiology Forecast (2024-2034)
7.7.3 Epidemiology by Age (2018-2034)
7.7.4 Epidemiology by Gender (2018-2034)
7.7.5 Diagnosed Cases (2018-2034)
7.7.6 Patient Pool/Treated Cases (2018-2034)
7.8 Epidemiology Scenario - Spain
7.8.1 Epidemiology Scenario (2018-2023)
7.8.2 Epidemiology Forecast (2024-2034)
7.8.3 Epidemiology by Age (2018-2034)
7.8.4 Epidemiology by Gender (2018-2034)
7.8.5 Diagnosed Cases (2018-2034)
7.8.6 Patient Pool/Treated Cases (2018-2034)
7.9 Epidemiology Scenario - Japan
7.9.1 Epidemiology Scenario (2018-2023)
7.9.2 Epidemiology Forecast (2024-2034)
7.9.3 Epidemiology by Age (2018-2034)
7.9.4 Epidemiology by Gender (2018-2034)
7.9.5 Diagnosed Cases (2018-2034)
7.9.6 Patient Pool/Treated Cases (2018-2034)
8 KERNICTERUS - TREATMENT ALGORITHM, GUIDELINES, AND MEDICAL PRACTICES
8.1 Guidelines, Management and Treatment
8.2 Treatment Algorithm
9 KERNICTERUS - UNMET NEEDS
10 KERNICTERUS - KEY ENDPOINTS OF TREATMENT
11 KERNICTERUS - MARKETED PRODUCTS
11.1 List of Kernicterus Marketed Drugs Across the Top 7 Markets
11.1.1 Drug Name – Company Name
11.1.1.1 Drug Overview
11.1.1.2 Mechanism of Action
11.1.1.3 Regulatory Status
11.1.1.4 Clinical Trial Results
11.1.1.5 Sales Across Major Markets
Kindly note that the complete list of marketed drugs has been provided in the report.
12 KERNICTERUS - PIPELINE DRUGS
12.1 List of Kernicterus Pipeline Drugs Across the Top 7 Markets
12.1.1 Drug Name – Company Name
12.1.1.1 Drug Overview
12.1.1.2 Mechanism of Action
12.1.1.3 Clinical Trial Results
12.1.1.4 Safety and Efficacy
12.1.1.5 Regulatory Status
Kindly note that the complete list of pipeline drugs has been provided in the report.
13. KERNICTERUS - ATTRIBUTE ANALYSIS OF KEY MARKETED AND PIPELINE DRUGS
14. KERNICTERUS – CLINICAL TRIAL LANDSCAPE
14.1 Drugs by Status
14.2 Drugs by Phase
14.3 Drugs by Route of Administration
14.4 Key Regulatory Events
15 KERNICTERUS - MARKET SCENARIO
15.1 Market Scenario - Key Insights
15.2 Market Scenario - Top 7 Markets
15.2.1 Kernicterus - Market Size
15.2.1.1 Market Size (2018-2023)
15.2.1.2 Market Forecast (2024-2034)
15.2.2 Kernicterus - Market Size by Therapies
15.2.2.1 Market Size by Therapies (2018-2023)
15.2.2.2 Market Forecast by Therapies (2024-2034)
15.3 Market Scenario - United States
15.3.1 Kernicterus - Market Size
15.3.1.1 Market Size (2018-2023)
15.3.1.2 Market Forecast (2024-2034)
15.3.2 Kernicterus - Market Size by Therapies
15.3.2.1 Market Size by Therapies (2018-2023)
15.3.2.2 Market Forecast by Therapies (2024-2034)
15.3.3 Kernicterus - Access and Reimbursement Overview
15.4 Market Scenario - Germany
15.4.1 Kernicterus - Market Size
15.4.1.1 Market Size (2018-2023)
15.4.1.2 Market Forecast (2024-2034)
15.4.2 Kernicterus - Market Size by Therapies
15.4.2.1 Market Size by Therapies (2018-2023)
15.4.2.2 Market Forecast by Therapies (2024-2034)
15.4.3 Kernicterus - Access and Reimbursement Overview
15.5 Market Scenario - France
15.5.1 Kernicterus - Market Size
15.5.1.1 Market Size (2018-2023)
15.5.1.2 Market Forecast (2024-2034)
15.5.2 Kernicterus - Market Size by Therapies
15.5.2.1 Market Size by Therapies (2018-2023)
15.5.2.2 Market Forecast by Therapies (2024-2034)
15.5.3 Kernicterus - Access and Reimbursement Overview
15.6 Market Scenario - United Kingdom
15.6.1 Kernicterus - Market Size
15.6.1.1 Market Size (2018-2023)
15.6.1.2 Market Forecast (2024-2034)
15.6.2 Kernicterus - Market Size by Therapies
15.6.2.1 Market Size by Therapies (2018-2023)
15.6.2.2 Market Forecast by Therapies (2024-2034)
15.6.3 Kernicterus - Access and Reimbursement Overview
15.7 Market Scenario - Italy
15.7.1 Kernicterus - Market Size
15.7.1.1 Market Size (2018-2023)
15.7.1.2 Market Forecast (2024-2034)
15.7.2 Kernicterus - Market Size by Therapies
15.7.2.1 Market Size by Therapies (2018-2023)
15.7.2.2 Market Forecast by Therapies (2024-2034)
15.7.3 Kernicterus - Access and Reimbursement Overview
15.8 Market Scenario - Spain
15.8.1 Kernicterus - Market Size
15.8.1.1 Market Size (2018-2023)
15.8.1.2 Market Forecast (2024-2034)
15.8.2 Kernicterus - Market Size by Therapies
15.8.2.1 Market Size by Therapies (2018-2023)
15.8.2.2 Market Forecast by Therapies (2024-2034)
15.8.3 Kernicterus - Access and Reimbursement Overview
15.9 Market Scenario - Japan
15.9.1 Kernicterus - Market Size
15.9.1.1 Market Size (2018-2023)
15.9.1.2 Market Forecast (2024-2034)
15.9.2 Kernicterus - Market Size by Therapies
15.9.2.1 Market Size by Therapies (2018-2023)
15.9.2.2 Market Forecast by Therapies (2024-2034)
15.9.3 Kernicterus - Access and Reimbursement Overview
16 KERNICTERUS - RECENT EVENTS AND INPUTS FROM KEY OPINION LEADERS
17 KERNICTERUS MARKET - SWOT ANALYSIS
17.1 Strengths
17.2 Weaknesses
17.3 Opportunities
17.4 Threats
18 KERNICTERUS MARKET – STRATEGIC RECOMMENDATIONS
19 APPENDIX
